• 대한의생명과학회지
• /
• 제11권4호
• /
• pp.509-515
• /
• 2005

This study was conducted to determine the kinetics of cyclohexane metabolites (the biomarker on cyclohexane exposure), the changes of hepatic cyclohexane metabolizing enzyme activities and the metabolites of cyclohexane in urine or serum. The rats were sacrificed at 2, 4, 8, 12 and 24 hr after administration of one dose of cyclohexane (1.56 g/kg body weight, i.p.). The metabolites of cyclohexane in urine were identified as cyclohexanol, cyclohexanone, trans-l,2-cyclohexanediol and 1,4-cyclohexanediol with cyclohexane metabolite being 124.00, 0.78, 23.28 and 2.75 (g/g of creatinine, $1\times10^{-3}$). Most of the cyclohexanol and trans-l,2-cyclohexanediol were determined to be in the form of $\beta-glucuronide$ conjugates, whereas cyclohexanone and 1 ,4-cyclohexanediol were found as free forms. In toxicokinetics of serum cyclohexane metabolites, cyclohexanol showed a rapid increase, reaching the plateau at 4 hr, after this time rapidly decreased throughout 24 hr. Changes of cyclohexanone also showed the similar pattern with cyclohexanol except somewhat lower concentration. Trans-l,2-cyclohexanediol, however, showed a gradual increase until 12 hr with the continued same levels throughout 24 hr. On the other hand, 1,4-cyclohexanediol was detected as trace levels at 4 and 12 hr, respectively. The administration of cyclohexane led to a significant increase of hepatic aniline hydroxylase activity from 2 to 8 hr. The activity of hepatic alcohol dehydrogenase showed a significant increase at 4 hr and then were recovered to the level of the control at 24 hr. On the other hand, there were no differences in liver weightlbody weight between the control and cyclohexane-treated animals. However, there were the changes of aniline hydroxylase and alcohol dehydrogenase activities on time-dependent pattern after cyclohexane treatment, which influence on the degree of cyclohexane metabolites both in blood and urine. These results suggest that differential determination of cyclohexane metabolites in urine and serum may be able to be as a biomarker of cyclohexane-exposure in the body. But in this fields further study is needed.

• Journal of Pharmaceutical Investigation
• /
• 제22권3호
• /
• pp.173-183
• /
• 1992

To study the feasibility of transmucosal delivery of $[D-ala^2]-methionine$ enkephalinamide (YAGFM), its enzymatic degradation and stabilization in various rabbit mucosal extracts were investigated by HPLC method. The degradation of YAGFM was observed to follow the first-order kinetics and the half-lives of YAGFM in the nasal, rectal and vaginal mucosal extracts were found to be 25.7, 3.0 and 7.8 hr, respectively. However, there was no significant difference in degradation rates of YAGFM between the mucosal and serosal extracts obtained from the same mucosal membrane. This finding suggests that even a synthetic enkephalin analog, which is designed to be resistent to aminopeptidases, needs to be fully protected from the enzymatic degradation in mucosal sites for the delivery of the analog through mucosal routes. To inhibit the degradation of YAGFM in various mucosal extracts, effects of enzyme inhibitors such as bestatin (BS), amastatin (AM), thiorphan (TP), thimerosal (TM) and EDTA, alone or in combination, and modified cyclodextrins were observed by assaying YAGFM staying intact during 24 hr-incubation at $37^{\circ}C$. It was found from the results that mixed inhibitors such as TM (0.5 mM)/EDTA (5 mM) or AM $(50{\mu}M)/TM$ (0.5 mM)/EDTA (5 mM) provided very useful means for the stabilization in various mucosal extracts. The latter was found to protect YAGFM from the degradation in the nasal, rectal, and vaginal mucosal extracts by 90.9, 90.4 and 91.3%, respectively, after 24 hr-incubation, suggesting almost complete inhibition of YAGFM-degrading enzymes present in the incubation mixture. However, BS $(50{\mu}M)$, AM 50 $(50{\mu}M)$ or TP$(50{\mu}M)$ alone did not reveal sufficient inhibition except TM (0.5 mM) or EDTA (5 mM). The adddition of $2-hydroxylpropyl-{\beta}-cyclodextrin$(10%) to the nasal mucosal extract, and $dimethyl-{\beta}-cyclodextrin$(10%) to the rectal and vaginal mucosal extracts reduced the first-order rate constants for the degradation of YAGFM by 5.8, 17.3 and 8.9 times, respectively, compared to those with no additive.

• 대한화장품학회지
• /
• 제31권3호
• /
• pp.273-277
• /
• 2005

본 연구에서는 피지분비 억제 효과를 지닌 신규 화장품 원료를 대한민국 유래의 천연 식물에서 개발하고자 하였다. 다양한 식물 추출물의 5alpha-reductase에 대한 저해효과를 자외선 분광광도계를 이용한 효소 동력학적 분석법을 통하여 평가하였다. 효소 동력학적 분석을 위하여 각각 쥐의 간 조직과 배양된 인체 유래 피지선 세포에서 5alpha-reductase를 추출하였다. 그 결과, 5-AR에 대하여 뛰어난 저해효능을 보이는 3종의 식물 추출물을 선정하였고, 이들의 피지분비 억제 효과를 배양된 인체 유래 피지선 세포를 이용하여 분석하였다. 연구의 결과, 수십 종의 식물 추출물 중 해송 추출물이 가장 강력한 5-AR 저해능을 나타내었으며, 인체 유래 피지선 세포에 대하여 0.005% 농도로 처리한 경우 48%의 피지 생성량 감소 효과를 나타내었다. 해송 추출물은 피지 분비를 감소시켜 여드름이나 지루성 피부염과 같은 피부 질환에 효과를 지닌 화장품의 원료로 사용될 수 있을 것이다.

• 공업화학
• /
• 제21권6호
• /
• pp.689-693
• /
• 2010

톨루엔에 녹인 천연고무를 탄소가루의 결합재로 사용하여 바이오센서를 제작하였을 때, 반죽은 용매가 증발한 후 기계적 물성을 보였다. 이 특성은 탄소반죽전극 실용화의 선행 조건을 만족시키는 것으로, 이 특성의 활용성을 살펴보기 위하여 과산화수소 정량을 위한 바이오센서를 제작하고, 그것의 전기화학적인 정량 및 정성적 특성을 파악하기 위하여 여러 가지 속도론적 파라메타, 즉 대칭인자(0.37), 교환전류밀도($i_0$, $0.075mAcm^{-2}$), 이중층의 축전용량($C_d$, $9.7{\times}10^{-3}F$), 시간상수(${\tau}_A$, 0.92 s), 최대전류($i_{max}$, $5.92{\times}10^{-7}Acm^{-2}$), Michaelis 상수($K_M$, $1.99{\times}10^{-3}M$) 및 기타 상수들을 도출하였다. 이 실험적 결과는 천연고무가 탄소가루의 결합재로 활용될 수 있음을 보여 주었다.

• Bulletin of the Korean Chemical Society
• /
• 제27권5호
• /
• pp.657-662
• /
• 2006

Identification of accessible sites in targeted RNAs is a major limitation to the effectiveness of antisense oligonucleotides. A class of antisense oligodeoxynucleotides, known as the “10-23” DNA enzyme or DNAzyme, which is a small catalytic DNA, has been shown to efficiently cleave target RNA at purine-pyrimidine junctions in vitro. We have designed a strategy to identify accessible cleavage sites in the target RNA, which is hepatitis C virus nonstructural gene 3 (HCV NS3) RNA that encodes viral helicase and protease, from a pool of random DNAzyme library. A pool of DNAzymes of 58 nucleotides-length that possess randomized annealing arms, catalytic core sequence, and fixed 5'/3'-end flanking sequences was designed and screened for their ability to cleave the target RNA. The screening procedure, which includes binding of DNAzyme pool to the target RNA under inactive condition, selection and amplification of active DNAzymes, incubation of the selected DNAzymes with the target RNA, and target site identification on sequencing gels, identified 16 potential cleavage sites in the target RNA. Corresponding DNAzymes were constructed for the selected target sites and were tested for RNA-cleavage in terms of kinetics and accessibility. These selected DNAzymes were effective in cleaving the target RNA in the presence of $Mg^{2+}$. This strategy can be applicable to identify accessible sites in any target RNA for antisense oligonucleotides-based gene inactivation methods.

• KSBB Journal
• /
• 제22권1호
• /
• pp.62-65
• /
• 2007

대사 공학을 이용한 생산 균주 개발의 핵심 기술은 원하는 대사산물을 과량으로 얻기 위하여 기존의 대사회로에서 제거, 증폭, 변경을 시켜야 할 유전자를 선정하는 것이다. 대사조절 분석 기법은 대사 흐름이 특정 효소의 활성에 따라 어떻게 변하는지를 예측하는 기술이다. 본 논문에서는 대장균의 threonine 생합성 효소 반응 kinetic model과 대사조절 분석 기법을 이용하여 threonine 생합성 flux를 가장 효과적으로 증가시키기 위하여 활성 증가가 필요한 효소가 aspartate semialdehyde dehyogenase라는 것을 밝혔다. 이러한 결과를 확인하기 위하여 asd가 과발현된 vector와 threonine 생합성 경로의 다른 효소인 aspartate kinase를 coding하는 thrA를 과발현 시키는 vector를 제작하여 threonine 생산 균주인 TF5015에 형질전환하여 threonine 농도를 측정하였다. Flask 배양결과 대사조절 분석 기법으로 확인된 유전자 asd를 과발현시킬 경우가 생합성 경로의 다른 유전자를 과발현시킨 경우보다 더 높은 threonine 농도의 증가를 보였다. 이러한 연구 결과들은 효소 반응 kinetic model과 대사조절 분석 기법을 이용하여 원하는 product를 효율적으로 생산할 수 있는 생산 균주를 제작할 수 있게 할 것이다.

• 한국식품과학회지
• /
• 제14권2호
• /
• pp.125-129
• /
• 1982

식품(食品)의 열 처리 공정중에 일어나는 페르옥시다아제의 열(熱) 불활성화(不活性化) 특성(特性)을 알기 위하여 서양고추냉이 뿌리에서 4개의 페르옥시다아제 이소짐(isozyme A, B, C 및 D)을 분리하고 pH 7.0, 온도범위 $70{\sim}97^{\circ}C$에서 각 이소짐 별로 열(熱) 불활성화(不活性化) 실험(實驗)을 행하였다. 각 이소짐의 열 저항성이 서로 크게 달랐고 $80^{\circ}C$에서는 C, B, A, D의 순서로 열에 강하였으며 각 이소짐의 열 불활성화는 1차반응에서 벗어났다. 이소짐 A, B, C 및 D의 $D_{80}$값은 각각 594초, 1850초, 2050초 및 78초 이었고 z값은 각각 $24.0^{\circ}C$, $12.5^{\circ}C$, $18.0^{\circ}C$ 및 $23.7^{\circ}C$이었으며 조효소의 $D_{80}$값은 130초, z값은 $24.0^{\circ}C$이었다. 이소짐 C를 열처리 했을 때에는 원래의 효소분자보다 분자량이 큰 단백질과 작은 단백질이 생성되었으며 이들은 효소활성이 없었다.

• 약학회지
• /
• 제38권2호
• /
• pp.202-210
• /
• 1994

To investigate the feasibility of mucosal delivery of $[D-Ala^6]$ LHRH, a potent analogue of LHRH, enzymatic proteolysis of $[D-Ala^6]$ LHRH and inhibitory effect of medium chain fatty acid salts(MFA) were studied using rabbit mucosal homogenate. $[D-Ala^6]$ LHRH incubated in homogenates of rectal(RE), nasal(NA) and vaginal(VA) mucosa were assayed by HPLC. The degradation of $[D-Ala^6]$ LHRH followed the first order kinetics. The degradation products were found as $[D-Ala^6]$ $LHRH^{1-7}$(m-i), to a lesser extent, $[D-Ala^6]$ $LHRH^{1-9}$(m-ii) and $[D-Ala^6]$ $LHRH^{1-3}$(m-iii) by the method of amino acid analysis(PITC method). The formation of$[D-Ala^6]$ $LHRH^{1-7}$ was not inhibited by the addition of disodium ethylenediaminetetraacetic acid but inhibited by sodium tauro-24,25-dihydrofusidate, suggesting that endopeptidase 24.11(EP 24.11) cleaves the $Leu^7-Arg^8$ bond of $[D-Ala^6]$ LHRH and is the primary $[D-Ala^6]$ LHRH degrading enzyme. The patterns of $[D-Ala^6]$ LHRH degradation indicated that EP 24.11 exists in each mucosal homogenate with the order of RE>NA>VA. MFA significantly inhibited the proteolysis of $[D-Ala^6]$ LHRH. The addition of sodium caprate(1.0%) or sodium laurate(0.5%) to the each mucosal homogenate completely protected $[D-Ala^6]$ LHRH from the degradation.

• Asian-Australasian Journal of Animal Sciences
• /
• 제28권4호
• /
• pp.573-583
• /
• 2015

B-32 is one of a panel of monoclonal anti-idiotypic antibodies to growth hormone (GH) that we developed. To characterize and identify its potential role as a novel growth hormone receptor (GHR) agonist, we determined that B-32 behaved as a typical $Ab2{\beta}$ based on a series of enzyme-linked immunosorbent assay assays. The results of fluorescence-activated cell sorting, indirect immunofluorescence and competitive receptor binding assays demonstrated that B-32 specifically binds to the GHR expressed on target cells. Next, we examined the resulting signal transduction pathways triggered by this antibody in primary porcine hepatocytes. We found that B-32 can activate the GHR and Janus kinase (2)/signal transducers and activators of transcription (JAK2/STAT5) signalling pathways. The phosphorylation kinetics of JAK2/STAT5 induced by either GH or B-32 were analysed in dose-response and time course experiments. In addition, B32 could also stimulate porcine hepatocytes to secrete insulin-like growth factors-1. Our work indicates that a monoclonal anti-idiotypic antibody to GH (B-32) can serve as a GHR agonist or GH mimic and has application potential in domestic animal (pig) production.

• Advances in Traditional Medicine
• /
• 제7권5호
• /
• pp.477-484
• /
• 2008

The present study was aimed at investigating the hypouricemic and xanthine oxidase inhibitory activities of the various fractions of the hydromethanolic extract of the leaves of Coccinia grandis L. Voigt (Cucurbitaceae). The leaves of this species was used in traditional medicinal system for the treatment of gout, rheumatism, jaundice, bronchitis, fever, skin eruptions, wounds, etc. The degree of xanthine oxidase inhibition was determined in vitro by measuring the increase in absorbance at 295 nm associated with uric acid formation. Among the fractions tested, the chloroform fraction exhibited highest potency ($IC_{50}$ $17.8\;{\mu}g/ml$). This was followed by the pet-ether ($IC_{50}$ $29.7\;{\mu}g/ml$), ethyl acetate ($IC_{50}$ $41.2\;{\mu}g/ml$) and residual ($IC_{50}$ $47\;{\mu}g/ml$) fractions. The $IC_{50}$ value of allopurinol was $6.1\;{\mu}g/ml$. In addition, the hypouricemic and hepatic xanthine oxidase (XO)/xanthine dehydrogenase (XDH) inhibitory activities of the fractions were examined in vivo using oxonate (280 mg/kg, i.p.) induced hyperuricemic mice. At a dose of 200 mg/kg orally for 7 days, the pet-ether, chloroform and ethyl acetate fractions produced a significant (P < 0.01) reduction in serum urate level and also inhibited hepatic XO/XDH activities when compared to hyperuricemic mice. These inhibitory effects were weaker than that observed for the standard drug, allopurinol (10 mg/kg, p.o.). Lineweaver-Burk analysis of the enzyme kinetics indicated that the mode of inhibition was of a mixed type. These results suggest that the use of Coccinia grandis leaves for the treatment of gout could be attributed to its XO inhibitory activity.